Vima Therapeutics raised $60M in Series A funding, led by Atlas Venture. The funds will expand operations and R&D efforts.
Vima Therapeutics raised $60M in Series A funding, led by Atlas Venture. The funds will expand operations and R&D efforts.
05/30/25, 10:14 AM
Location
cambridgeMoney raised
$60 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Canaan, Access Industries, Atlas Venture
Vima Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $60M in Series A funding. The round was led by Atlas Venture, with participation from Access Industries and Canaan. The company intends to use the funds to expand operations and its R&D efforts. Vima is advancing a first-in-class oral therapy in clinical trials.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Vima Therapeutics is a clinical-stage biotechnology company providing treatments for dystonia and related movement disorders. The company is advancing an oral therapy designed to help patients improve control of their movement by targeting the root cause of the disease. It is currently working on VIM0423, a potential first-in-class oral therapy, which is in a Phase 1 clinical trial with plans to move into Phase 2 by the end of 2025.